Cargando…

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic mutations affecting methionine-41 (p.Met41) in UBA1. The VEXAS syndrome often overlaps with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Huijun, Zhang, Wenjun, Cai, Wenyu, Liu, Jinqin, Wang, Huijun, Qin, Tiejun, Xu, Zefeng, Li, Bing, Qu, Shiqiang, Pan, Lijuan, Huang, Gang, Gale, Robert Peter, Xiao, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976711/ https://www.ncbi.nlm.nih.gov/pubmed/33741056 http://dx.doi.org/10.1186/s40164-021-00217-2

Ejemplares similares

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant
por: Qu, Shiqiang, et al.
Publicado: (2022)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
por: Feng, Gege, et al.
Publicado: (2016)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes
por: Wang, Jingya, et al.
Publicado: (2016)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center
por: Liu, Dan, et al.
Publicado: (2022)

Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes: A retrospective study
por: Ai, Xiaofei, et al.
Publicado: (2021)

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
por: Zhang, Yudi, et al.
Publicado: (2022)

Myelodysplastic Syndrome Associated With Auto-Immune Inflammatory Disease in VEXAS Syndrome
por: Thomas, Vibha Taneja, et al.
Publicado: (2021)

RBC distribution width predicts thrombosis risk in polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
por: Huang, Huijun, et al.
Publicado: (2023)

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022)

VEXAS syndrome
por: Grayson, Peter C., et al.
Publicado: (2021)

VEXAS-Syndrom
por: Zeeck, M., et al.
Publicado: (2022)

Thrombosis in VEXAS syndrome
por: Oo, Thet Mon, et al.
Publicado: (2021)

VEXAS Syndrome—Review
por: Zhang, Yue, et al.
Publicado: (2023)

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
por: Yan, Xin, et al.
Publicado: (2023)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

VEXAS syndrome with cutaneous nodules
por: Argobi, Yahya
Publicado: (2021)

VEXAS syndrome: a diagnostic puzzle
por: Ruffer, Nikolas, et al.
Publicado: (2023)

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
por: Luo, Xueping, et al.
Publicado: (2018)

VEXAS Syndrome: A Novelty in MDS Landscape
por: Templé, Marie, et al.
Publicado: (2022)

VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia
por: Austestad, Janne, et al.
Publicado: (2023)

Intrapatient competition of VEXAS syndrome and CML clones
por: Djerbi, Nadia, et al.
Publicado: (2023)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

Recurrent superior orbital fissure syndrome associated with VEXAS syndrome
por: Myint, Katie, et al.
Publicado: (2023)

Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome
por: Goyal, Amrita, et al.
Publicado: (2022)

Vexas: A new syndrome not always associated with hemopathy
por: Thomas, Benoît, et al.
Publicado: (2021)

Vasculitis associated with VEXAS syndrome: A literature review
por: Watanabe, Ryu, et al.
Publicado: (2022)

Quantitative Assessment of Vacuolization of Myeloid Precursors in VEXAS Syndrome
por: Rabut, Audrey, et al.
Publicado: (2023)

Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome
por: Merrill, Andrea L., et al.
Publicado: (2011)

Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome
por: Lacombe, Valentin, et al.
Publicado: (2022)

Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome
por: Vitale, Antonio, et al.
Publicado: (2022)

VEXAS syndrome: a newly discovered systemic rheumatic disorder
por: Kucharz, Eugenisz J.
Publicado: (2023)

VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)
por: Stubbins, Ryan J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tabjmvs2qc43ajtnt5mo8snfkp